Saturday, 17 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

LAVIDE HOLDING Stock Went Down By Over 32% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of LAVIDE HOLDING (AEX-Index: LVIDE.AS) fell by a staggering 32.43% in 21 sessions from €0.37 to €0.25 at 01:12 EST on Monday, after five sequential sessions in a row of losses. AEX-Index is dropping 0.64% to €722.43, following the last session's downward trend.

About LAVIDE HOLDING

Lavide Holding N.V. does not have significant operations. Previously, it was engaged in the provision of integrated information technology solutions for medium to large-sized companies and organizations. The company was formerly known as Qurius N.V. and changed its name to Lavide Holding N.V. in July 2013. Lavide Holding N.V. was incorporated in 1998 and is based in Sluis, the Netherlands.

Earnings Per Share

As for profitability, LAVIDE HOLDING has a trailing twelve months EPS of €-0.025.

More news about LAVIDE HOLDING (LVIDE.AS).

Categories

stockMarket

Tags

Stock PricePrice DownLAVIDE HOLDINGMarket Session NowStock Price DownStock Market NowMarket SessionStock MarketStockLVIDE.AS
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com